Seeking Alpha

Sanofi (SNY -2%) and Regeneron (REGN -2.5%) today announce that they are enrolling patients in...

Sanofi (SNY -2%) and Regeneron (REGN -2.5%) today announce that they are enrolling patients in more than 10 late-stage clinical trials , named Odyssey, for a potentially first-in-class cholesterol - lowering drug targeting an enzyme called PCSK9. Odyssey will involve more than 22K patients, including 18K in a trial to measure cardiovascular outcomes such as heart attacks and strokes.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs